RWJ 67657

Drug Profile

RWJ 67657

Alternative Names: RWJ-67657

Latest Information Update: 27 May 2010

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class Antirheumatics; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV-1 infections; Rheumatoid arthritis

Most Recent Events

  • 16 Nov 2004 A preclinical study has been added to the Rheumatic Disease pharmacodynamics section
  • 09 Aug 2004 Data presented at the 15th International AIDS Conference (IAC-2004) have been added to the Viral Infections antimicrobial activity section
  • 24 Jun 2004 Data presented at the Annual European Congress of Rheumatology (EULAR-2004) have been added to the Rheumatic Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top